#China #Shanghai #biotechnology #Antengene #T-Cell Engagers

Antengene Reports Significant First TCE Out-Licensing and Strategic Achievements for 2025

Antengene Corporation Limited, a biotech company known for its cutting-edge therapeutic discoveries, recently announced its full-year financial results for 2025, wrapping up a year filled with substantial advancements and strategic partnerships. This announcement not only highlights the company's commitment to long-term growth but also showcases the promising value of its proprietary platforms, specifically the AnTenGager™ T-cell engager (TCE) platform.

Key Highlights of 2025

During 2025, Antengene strengthened its position by establishing a late-stage clinical pipeline and successfully commercializing its product XPOVIO® across ten Asia-Pacific markets, adding substantial revenue streams to the company.

One of the standout moments of the year was the global licensing agreement with UCB for ATG-201, a CD19 x CD3 TCE. This first out-licensing transaction illuminates the strong potential of Antengene's proprietary platform, marking a vital turning point towards generating profit in 2026. With an immediate upfront payment of USD 60 million and potential future payments exceeding USD 1.1 billion, the deal underscores the global competitiveness of Antengene’s platform.

Antengene's CEO, Dr. Jay Mei, stated, "The agreements we’ve formed reflect the foundation laid over years. As we enter 2026, we are well-positioned to turn this established groundwork into significant value creation."

Advancements in Clinical Programs

Antengene’s late-stage clinical trials have made impressive headway in areas such as gastric cancer treatment with ATG-022, a CLDN18.2 antibody-drug conjugate. Recent results indicate remarkable efficacy and a favorable safety profile; as the company prepares to launch pivotal Phase III trials in 2026.

Moreover, the oral small molecule inhibitor, ATG-037, is demonstrating promising results in combination therapies for checkpoint inhibitor-resistant tumors. These key clinical programs represent pivotal value drivers for Antengene, aimed at addressing significant unmet medical needs.

Innovative Platforms and Future Outlook

The AnTenGager™ TCE platform, which leverages advanced technologies for effective and safe therapeutic engagements, remains open for global collaborations, enhancing potential revenue streams from various partnerships.

As the company continues to pioneer innovative scientific platforms, expectations lend favor to sustainable growth alongside strict cost management. With a robust pipeline, rich in diverse treatment modalities, Antengene is set to reinforce its R&D engine well into the future.

Antengene's strong cash reserves of RMB 734 million establish a solid foundation for executing long-term strategies while advancing pivotal clinical programs toward proof-of-concept stages.

In summary, Antengene’s 2025 report presents a formidable blend of strategic advancements, expanding revenue potentials, and innovative therapeutic approaches. As they prepare for 2026, the spotlight is firmly on how these developments will translate into improved health outcomes and solid financial performance for the company and its stakeholders.

For further insights into Antengene’s promising year and future objectives, check their comprehensive financial announcement in the Investor Relations section of the company's official website.